Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings

References

• 1 Lewis DA, Curley AA, Glausier JR, et al.: Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012; 35:57–67 Crossref, Medline, Google Scholar
• 2 Ayalew M, Le-Niculescu H, Levey DF, et al.: Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry 2012; 17:887–905 Crossref, Medline, Google Scholar
• 3 Straub RE, Lipska BK, Egan MF, et al.: Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry 2007; 12:854–869 Crossref, Medline, Google Scholar
• 4 Menzies L, Ooi C, Kamath S, et al.: Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch Gen Psychiatry 2007; 64:156–167 Crossref, Medline, Google Scholar
• 5 Uhlhaas PJ, Singer W: Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 2010; 11:100–113 Crossref, Medline, Google Scholar
• 6 Verhoeff NP, Soares JC, D’Souza CD, et al.: [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 1999; 91:163–173 Crossref, Medline, Google Scholar
• 7 Frankle WG, Cho RY, Narendran R, et al.: Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology 2009; 34:624–633 Crossref, Medline, Google Scholar
• 8 Stokes PR, Myers JF, Kalk NJ, et al.: Acute increases in synaptic GABA detectable in the living human brain: a [¹¹C]Ro15-4513 PET study. Neuroimage 2014; 99:158–165 Crossref, Medline, Google Scholar
• 9 Frankle WG, Cho RY, Prasad KM, et al.: In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients. Am J Psychiatry 2015; 172:1148–1159 Link, Google Scholar
• 10 Tayoshi S, Nakataki M, Sumitani S, et al.: GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2010; 117:83–91 Crossref, Medline, Google Scholar
• 11 Rowland LM, Kontson K, West J, et al.: In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 2013; 39:1096–1104 Crossref, Medline, Google Scholar
• 12 Stan AD, Ghose S, Zhao C, et al.: Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia. Mol Psychiatry 2015; 20:433–439. Crossref, Medline, Google Scholar
• 13 Yoon JH, Maddock RJ, Rokem A, et al.: GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 2010; 30:3777–3781 Crossref, Medline, Google Scholar
• 14 Kelemen O, Kiss I, Benedek G, et al.: Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex. Prog Neuropsychopharmacol Biol Psychiatry 2013; 47:13–19 Crossref, Medline, Google Scholar
• 15 Marsman A, Mandl RC, Klomp DW, et al.: GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study. Neuroimage Clin 2014; 6:398–407 Crossref, Medline, Google Scholar
• 16 Rowland LM, Krause BW, Wijtenburg SA, et al.: Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study. Mol Psychiatry (Epub ahead of print, March 31, 2015) Google Scholar
• 17 Goto N, Yoshimura R, Moriya J, et al.: Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T proton MRS study. Schizophr Res 2009; 112:192–193 Crossref, Medline, Google Scholar
• 18 Savostyanova AA, van der Veen JW, Stern A, et al.: GABA levels in medial prefrontal cortex of patients with schizophrenia: a proton magnetic resonance spectroscopy (1H-MRS) study. Biol Psychiatry 2007; 61:77S Google Scholar
• 19 Kegeles LS, Mao X, Stanford AD, et al.: Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2012; 69:449–459 Crossref, Medline, Google Scholar
• 20 Ongür D, Prescot AP, McCarthy J, et al.: Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry 2010; 68:667–670 Crossref, Medline, Google Scholar
• 21 Goto N, Yoshimura R, Kakeda S, et al.: No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1480–1483 Crossref, Medline, Google Scholar
• 22 Marenco S, Geramita M, van der Veen JW, et al.: Genetic association of ErbB4 and human cortical GABA levels in vivo. J Neurosci 2011; 31:11628–11632 Crossref, Medline, Google Scholar
• 23 Marenco S, Savostyanova AA, van der Veen JW, et al.: Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology 2010; 35:1708–1717 Crossref, Medline, Google Scholar
• 24 Meyer-Lindenberg A, Weinberger DR: Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006; 7:818–827 Crossref, Medline, Google Scholar
• 25 Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276 Crossref, Medline, Google Scholar
• 26 Wallwork RS, Fortgang R, Hashimoto R, et al.: Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 2012; 137:246–250 Crossref, Medline, Google Scholar
• 27 Geramita M, Van der Veen JW, Barnett AS, et al.: Reproducibility of prefrontal γ-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed 2011; 24:1089–1098 Crossref, Medline, Google Scholar
• 28 Kegeles LS, Mao X, Gonsalez R, et al.: Evaluation of anatomic variation in macromolecule contribution to the GABA signal using metabolite nulling and the J-editing technique at 3.0 T. Proc Intl Soc Mag Reson Med 2007; 15:1391 Google Scholar
• 29 Ashburner J, Friston K: Multimodal image coregistration and partitioning: a unified framework. Neuroimage 1997; 6:209–217 Crossref, Medline, Google Scholar
• 30 Bustillo J, Barrow R, Paz R, et al.: Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 2006; 31:751–756 Crossref, Medline, Google Scholar
• 31 See RE, Lynch AM: Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuroreport 1995; 6:1795–1798 Crossref, Medline, Google Scholar
• 32 Konopaske GT, Bolo NR, Basu AC, et al.: Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain. Psychopharmacology (Berl) 2013; 230:57–67 Crossref, Medline, Google Scholar
• 33 McLoughlin GA, Ma D, Tsang TM, et al.: Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 2009; 8:1943–1952 Crossref, Medline, Google Scholar
• 34 Grimm JW, See RE: Chronic haloperidol-induced alterations in pallidal GABA and striatal D(1)-mediated dopamine turnover as measured by dual probe microdialysis in rats. Neuroscience 2000; 100:507–514 Crossref, Medline, Google Scholar
• 35 See RE, Chapman MA: The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Crit Rev Neurobiol 1994; 8:85–124 Medline, Google Scholar
• 36 Osborne PG, O’Connor WT, Beck O, et al.: Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA, and acetylcholine release. Brain Res 1994; 634:20–30 Crossref, Medline, Google Scholar
• 37 Lipska BK, Lerman DN, Khaing ZZ, et al.: Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. Eur J Neurosci 2003; 18:391–402 Crossref, Medline, Google Scholar
• 38 Zink M, Schmitt A, May B, et al.: Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr Res 2004; 66:151–157 Crossref, Medline, Google Scholar
• 39 Epperson CN, O’Malley S, Czarkowski KA, et al.: Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry 2005; 57:44–48 Crossref, Medline, Google Scholar
• 40 Michels L, Martin E, Klaver P, et al.: Frontal GABA levels change during working memory. PLoS One 2012; 7:e31933 Crossref, Medline, Google Scholar